Standard of care in patients with unresectable stage III non-small cell lung cancer (NSCLC) is concurrent chemo-radiotherapy followed by immunotherapy. Here, the authors report a phase II trial investigating induction chemo-immunotherapy (atezolizumab, carboplatin and paclitaxel) followed by concurrent chemoradiotherapy and immunotherapy maintenance in patients with stage III NSCLC.
- Mariano Provencio
- Begoña Campos
- Alberto Cruz-Bermúdez
